Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Vaccines (Basel) ; 10(8)2022 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-36016089

RESUMEN

A United States Government (USG) interagency group, the Filovirus Animal Non-Clinical Group (FANG), has been established to support the development of biodefense medical countermeasures (MCMs). As both vaccines and therapeutics are licensed using "non-traditional pathways", such as the U.S. Food and Drug Administration's (FDA) Animal Rule (AR), non-human primate (NHP) models and associated assays have been developed and standardized across BSL4 testing sites to evaluate candidate products. Vaccine candidates are evaluated using these NHP models, and through this public-private partnership, a meta-analysis of NHP control data has been conducted and submitted to the FDA as a master file. This is an example of how existing NHP control data can be leveraged in lieu of conducting separate natural history studies at multiple testing facilities to demonstrate the consistency of a standardized animal model for vaccine development. As a result, animal use can be minimized and the duplication of effort avoided, thus reducing the amount of time needed to conduct additional studies, as well as the cost of vaccine candidate development. This successful strategy may be applied to other pathogens of high consequence for vaccine development, and shows how strategic preparedness for biodefense can be leveraged in response to outbreaks and public health emergencies.

2.
Sci Transl Med ; 7(286): 286ps11, 2015 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-25947159

RESUMEN

A December 2014 meeting reviewed Ebola virus immunology relevant to vaccine development, including Ebola prevention, immunity, assay standardization, and regulatory considerations. Vaccinated humans appear to achieve immune responses comparable in magnitude with those associated with protection in nonhuman primates, suggesting that immunological data could be used to demonstrate vaccine efficacy.


Asunto(s)
Vacunas contra el Virus del Ébola/uso terapéutico , Fiebre Hemorrágica Ebola/inmunología , Fiebre Hemorrágica Ebola/prevención & control , Adenoviridae/inmunología , África Occidental , Animales , Anticuerpos Antivirales/inmunología , Centers for Disease Control and Prevention, U.S. , Congresos como Asunto , Vacunas contra el Virus del Ébola/inmunología , Ebolavirus/inmunología , Humanos , Inmunidad Humoral , National Institute of Allergy and Infectious Diseases (U.S.) , Ensayos Clínicos Controlados Aleatorios como Asunto , Estados Unidos , United States Food and Drug Administration , Vacunación
3.
Hum Vaccin Immunother ; 9(7): 1591-7, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23428906

RESUMEN

The Defense Threat Reduction Agency's Joint Science and Technology Office manages the Chemical and Biological Defense Program's Science and Technology portfolio. The Joint Science and Technology Office's mission is to invest in transformational ideas, innovative people and actionable technology development for Chemical and Biological Defense solutions, with the primary goal to deliver Science and Technology products and capabilities to the warfighter and civilian population that outpace the threat. This commentary focuses on one thrust area within this mission: the Vaccine program of the Joint Science and Technology Office's Translational Medical Division. Here, we will describe candidate vaccines currently in the S&T pipeline, enabling technologies that should facilitate advanced development of these candidates into FDA licensed vaccines, and how the ever-changing biological threat landscape impacts the future of biodefense vaccines.


Asunto(s)
Armas Biológicas , Guerra Biológica/prevención & control , Pandemias/prevención & control , Vacunas , Toxinas Bacterianas/inmunología , Toxinas Bacterianas/toxicidad , Descubrimiento de Drogas , Encefalitis Viral/inmunología , Encefalitis Viral/prevención & control , Encefalitis Viral/virología , Fiebres Hemorrágicas Virales/inmunología , Fiebres Hemorrágicas Virales/prevención & control , Fiebres Hemorrágicas Virales/virología , Humanos , Estados Unidos , United States Department of Defense
4.
J Leukoc Biol ; 84(4): 1011-8, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18591414

RESUMEN

Antigen presentation by class II MHC molecules in the uninfected host is a multi-step process involving key functions provided by specific cathepsins (Cat) and the peptide editor DM. Herein, we examined the requirement for each of these components in mice to control a low-dose aerosol infection with Mycobacterium tuberculosis (MTB). Mice lacking Cat B, -L, or -S were similar to wild-type in their ability to control the growth and dissemination of MTB. In contrast, DM(-/-) mice failed to limit MTB growth and showed approximately 100-fold higher bacterial burden in the lung and spleen (5-6 weeks postinfection) as compared with wild-type and Cat-deficient mice. Histopathology revealed impaired cellular recruitment and altered granuloma formation in the lungs of MTB-infected DM(-/-) mice. Moreover, despite impaired thymic selection in Cat L(-/-) and DM(-/-) mice, MTB-specific CD4(+) T cells were elicited only in the former. The lower numbers of MTB-specific CD4(+) T cells available in Cat L(-/-) mice as compared with wild-type animals were sufficient to control MTB growth and dissemination. In addition, DM(-/-) macrophages infected with MTB in vitro were unable to stimulate pathogen-specific T cells. The data indicate that the majority of antigens derived from MTB are loaded onto nascent class II MHC molecules via the classical DM-dependent pathway.


Asunto(s)
Catepsinas/metabolismo , Cisteína Endopeptidasas/metabolismo , Proteínas Serina-Treonina Quinasas/deficiencia , Tuberculosis/transmisión , Aerosoles , Animales , Células Presentadoras de Antígenos/inmunología , Linfocitos T CD4-Positivos/inmunología , Catepsina L , Catepsinas/deficiencia , Cruzamientos Genéticos , Cisteína Endopeptidasas/deficiencia , Antígenos de Histocompatibilidad Clase II/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Ratones Noqueados , Mycobacterium tuberculosis/crecimiento & desarrollo , Mycobacterium tuberculosis/patogenicidad , Proteína Quinasa de Distrofia Miotónica , Tuberculosis/inmunología
5.
Int Immunol ; 18(6): 931-9, 2006 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16636015

RESUMEN

Mycobacterium tuberculosis-infected macrophages demonstrate diminished capacity to present antigens via class II MHC molecules. Since successful class II MHC-restricted antigen presentation relies on the actions of endocytic proteases, we asked whether the activities of cathepsins (Cat) B, S and L-three major lysosomal cysteine proteases-are modulated in macrophages infected with pathogenic Mycobacterium spp. Infection of murine bone marrow-derived macrophages with either Mycobacterium avium or M. tuberculosis had no obvious effect on Cat B or Cat S activity. In contrast, the activity of Cat L was altered in infected cells. Specifically, whereas the 24-kDa two-chain mature form of active Cat L predominated in uninfected cells, we observed an increase in the steady-state activity of the precursor single-chain (30 kDa) and 25-kDa two-chain forms of the enzyme in cells infected with either M. avium or M. tuberculosis. Pulse-chase analyses revealed that maturation of nascent, single-chain Cat L into the 25-kDa two-chain form was impaired in infected macrophages, and that maturation into the 24-kDa two-chain form did not occur. Consistent with these data, M. avium infection inhibited the IFNgamma-induced secretion of active two-chain Cat L by macrophages. Viable bacilli were not required to disrupt Cat L maturation, suggesting that a constitutively expressed mycobacterial component was responsible. The absence of the major active form of lysosomal Cat L in M. avium- and M. tuberculosis-infected macrophages may influence the types of T cell epitopes generated in these antigen-presenting cells, and/or the rate of class II MHC peptide loading.


Asunto(s)
Presentación de Antígeno/inmunología , Catepsinas/inmunología , Cisteína Endopeptidasas/inmunología , Macrófagos/inmunología , Mycobacterium avium/inmunología , Mycobacterium tuberculosis/inmunología , Tuberculosis/inmunología , Animales , Antígenos Bacterianos/inmunología , Células de la Médula Ósea/enzimología , Células de la Médula Ósea/inmunología , Células de la Médula Ósea/microbiología , Catepsina B/deficiencia , Catepsina L , Catepsinas/deficiencia , Activación Enzimática/inmunología , Epítopos de Linfocito T/inmunología , Genes MHC Clase II , Interferón gamma/inmunología , Macrófagos/enzimología , Macrófagos/microbiología , Ratones , Ratones Noqueados , Péptidos/inmunología , Procesamiento Proteico-Postraduccional/inmunología
6.
J Nurs Care Qual ; 21(2): 160-7, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16540785

RESUMEN

The purpose of this project was to organize the variables associated with the hospital readmission of patients with heart failure (HF) into a usable framework to inform clinical practice and facilitate administrative decision making. An integrated, systematic review of the literature was used as the research approach. A content analysis of the sample (31 research reports from the years 1986-2004) yielded multiple factors associated with the hospital readmission of HF patients. Factors and their definitions were extracted, grouped into like categories, and eventually classified into 5 domains-demographic, physiologic, psychosocial, patient functioning, and resource utilization. The resulting framework has clinical, research, and administrative implications in the delivery of care to HF patients.


Asunto(s)
Medicina Basada en la Evidencia/organización & administración , Insuficiencia Cardíaca/terapia , Readmisión del Paciente/estadística & datos numéricos , Actividades Cotidianas , Manejo de Caso , Toma de Decisiones en la Organización , Manejo de la Enfermedad , Estado de Salud , Insuficiencia Cardíaca/epidemiología , Insuficiencia Cardíaca/etiología , Humanos , Tiempo de Internación , Investigación en Administración de Enfermería , Evaluación en Enfermería , Investigación en Evaluación de Enfermería , Evaluación de Resultado en la Atención de Salud , Cooperación del Paciente , Alta del Paciente , Medición de Riesgo , Factores de Riesgo , Autocuidado , Estados Unidos/epidemiología
7.
Am J Transplant ; 4 Suppl 9: 13-26, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15113352

RESUMEN

By examining the sources, quality and organization of transplant data available, as well as making observations about data reporting patterns and accuracy, we hope to improve understanding of existing results, help researchers with study design and stimulate new exploratory initiatives. The primary data source, collected by the OPTN, has benefited from extensive recent technological advances. Transplant professionals now report patient and donor data more easily, quickly, and accurately, improving data timeliness and precision. Secondary sources may be incorporated, improving the accuracy and expanding the scope of analyses. For example, auxiliary mortality data allows more accurate survival analysis and conclusions regarding the completeness of center-reported post-transplant follow-up. Furthermore, such sources enable examination of outcomes not reported by centers, such as mortality after waiting list removal, providing more appropriate comparisons of waiting list and post-transplant mortality. Complex collection and reporting processes require specific analytical methods and may lead to potential pitfalls. Patterns in the timing of reporting adverse events differ from those for 'positive' events, yielding the need for care in choosing cohorts and censor dates to avoid bias. These choices are further complicated by the use of multiple sources of data, with different time lags and reporting patterns.


Asunto(s)
Trasplante/estadística & datos numéricos , Trasplante/normas , Humanos , Sistema de Registros , Investigación/normas , Obtención de Tejidos y Órganos/organización & administración , Obtención de Tejidos y Órganos/estadística & datos numéricos , Trasplante/tendencias , Resultado del Tratamiento , Estados Unidos
8.
Curr Opin Immunol ; 16(1): 96-102, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14734116

RESUMEN

The loading of class II MHC molecules with antigenic peptides is largely confined to the endocytic vesicles of specialized antigen-presenting cells (APCs), such as B cells, macrophages and dendritic cells. At first glance, the pathway utilized by each of these professional APCs to generate class II-peptide complexes on their surface appears to be indistinguishable. All three types of APC rely on the chaperone Ii for correct class II assembly and transport to the endocytic pathway, they all depend on the action of specific cysteine proteases to remove Ii from the class II-Ii complex, and they all utilize the class II-like molecule DM to facilitate peptide loading. A closer look, however, reveals subtle yet important differences in the class II maturation pathway between each of these APCs, which befit the unique roles these individual cells play in eliciting CD4(+) T-cell responses.


Asunto(s)
Presentación de Antígeno , Células Presentadoras de Antígenos/inmunología , Antígenos de Histocompatibilidad Clase II/metabolismo , Péptidos/inmunología , Animales , Ácido Aspártico Endopeptidasas/fisiología , Catepsinas/fisiología , Péptidos/metabolismo , Vesículas Transportadoras/fisiología
9.
J Immunol ; 169(11): 6149-53, 2002 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-12444118

RESUMEN

Polysaccharides of pathogenic extracellular bacteria commonly have negatively charged groups or no charged groups at all. These molecules have been considered classic T cell-independent Ags that do not elicit cell-mediated immune responses in mice. However, bacterial polysaccharides with a zwitterionic charge motif (ZPSs), such as the capsular polysaccharides of many strains of Bacteroides fragilis, Staphylococcus aureus, and Streptococcus pneumoniae type 1 elicit potent CD4(+) T cell responses in vivo and in vitro. The cell-mediated response to ZPS depends on the presence of both positively charged and negatively charged groups on each repeating unit of the polysaccharide. In this study, we define some of the requirements for the presentation of ZPS to CD4(+) T cells. We provide evidence that direct interactions of T cells with APCs are essential for T cell activation by ZPS. Monocytes, dendritic cells, and B cells are all able to serve as APCs for ZPS-mediated T cell activation. APCs lacking MHC class II molecules do not support this activity. Furthermore, mAb to HLA-DR specifically blocks ZPS-mediated T cell activation, while mAbs to other MHC class II and class I molecules do not. Immunoprecipitation of lysates of MHC class II-expressing cells following incubation with ZPS shows binding of ZPS and HLA-DR. Electron microscopy reveals colocalization of ZPS with HLA-DR on the cell surface and in compartments of the endocytic pathway. These results indicate that MHC class II molecules expressing HLA-DR on professional APCs are required for ZPS-induced T cell activation. The implication is that binding of ZPS to HLA-DR may be required for T cell activation.


Asunto(s)
Antígenos HLA-DR/metabolismo , Polisacáridos Bacterianos/farmacología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Animales , Presentación de Antígeno , Células Presentadoras de Antígenos/inmunología , Células Presentadoras de Antígenos/metabolismo , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Compartimento Celular , Membrana Celular/inmunología , Membrana Celular/metabolismo , Endosomas/inmunología , Endosomas/metabolismo , Humanos , Técnicas In Vitro , Iones , Activación de Linfocitos/efectos de los fármacos , Lisosomas/inmunología , Lisosomas/metabolismo , Ratones , Polisacáridos Bacterianos/química , Polisacáridos Bacterianos/metabolismo
11.
Curr Opin Immunol ; 14(1): 15-21, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11790528

RESUMEN

Antigen presentation by MHC class II molecules relies on the action of endocytic proteases, which are differentially expressed in antigen-presenting cells and are regulated by different components of the immune system. Endocytic enzymes process and convert exogenous antigens into peptidic determinants capable of interaction with MHC class II molecules. Chemical and genetic tools have recently been developed to study the role of lysosomal proteases in antigen presentation.


Asunto(s)
Presentación de Antígeno , Endopeptidasas/inmunología , Antígenos de Histocompatibilidad Clase II/inmunología , Animales , Endocitosis/inmunología , Humanos , Ratones , Fagosomas/inmunología , Proteoma
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA